As of 2024, the Company operates in two segments: Biotechnology and Technology. The Biotechnology Segment focuses on developing its biotechnology product pipeline and does not generate revenue. It reported total assets of $13,783,575 as of December 31, 2025, and $8,366,785 as of December 31, 2024. This segment had no sales in 2025 and 2024, with operating expenses of $13,540,971 in 2025 and $10,054,488 in 2024, resulting in net losses from operations of $(13,540,971) in 2025 and $(10,054,488) in 2024.
The Technology Segment generates revenue by acquiring technology assets to support and enhance operational capabilities through advanced technologies. It reported total assets of $2,370,346 as of December 31, 2025, and $541,875 as of December 31, 2024. In 2025, the Technology Segment recorded sales of $1,363,045, cost of goods sold of $180,625, operating expenses of $684,947, and a net gain from operations of $497,473. It had no sales or expenses in 2024.
The Company’s segment structure reflects differences in future potential revenue streams, customer base, reporting structure, and management’s organization around future revenue-generating activities.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %